Corcept Therapeutics (CORT) Stock Price, Quote & News

Company Profile

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery....

Industry: Biotechnology

Sector: Healthcare

Phone: 650 327 3270

Website: www.corcept.com

Address:

101 Redwood Shores Parkway, Redwood City, United States

aristocks Jul. 30 at 6:50 PM

$CORT just sold few hundred shares... Core position still intact, but it was getting to big comparing the rest of my portfolio... Still so bullish. Saw the new PT of 165$ from some analysts.. Amazing :)

0 · Reply

flychicken1991 Jul. 30 at 6:01 PM

$CORT Positive (86%): The earnings beat and raised 2026 outlook put direct upward pressure on CORT's stock price by increasing expected future sales and earnings, with the reported 27.9% gain indicating that a substantial positive repricing was already underway. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/5f16e90dc3a65107?utm_source=stocktwits&utm_medium=story_url

0 · Reply

StocktwitsNews Jul. 30 at 5:53 PM

These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months $CORT $ANIK $XBI https://stocktwits.com/news/equity/markets/cort-stock-52-week-high-q2-results-anika-therapeutics-outlook/cZN5JErRJ2c

0 · Reply

Larry_wildman Jul. 30 at 5:17 PM

$CORT $GIFT

0 · Reply

Dragan7 Jul. 30 at 3:08 PM

$CORT "Corcept Therapeutics (CORT) is significantly expanding its neuroscience footprint following landmark clinical results for its proprietary selective cortisol modulator, dazucorilant, to treat amyotrophic lateral sclerosis (ALS)"! There is no cure for ALS ( Lou Gehrig ), 87% reduction in the risk of death is remarkable! "87% Risk Reduction: Patients treated with the 300 mg dose of dazucorilant experienced a massive 87% reduction in the risk of death compared to placebo over a two-year tracking period (p < 0.0001)"

1 · Reply

Dragan7 Jul. 30 at 3:00 PM

$CORT Second point: they are profitable, and highly candidate for M&A. Pharma must be looking.

0 · Reply

fda_tracker Jul. 30 at 2:57 PM

$CORT New PDUFA Date 2026-12-17 CORCEPT THERAPEUTICS INC Link: https://www.sec.gov/Archives/edgar/data/1088856/000162828026050613/cort-20260630.htm Calendar: http://www.fdatracker.com/fda-calendar/

0 · Reply

RazorbackAJ Jul. 30 at 2:55 PM

$CORT Up 9% from this call and stop loss moved to $115 and in deep profits. Follow so you don't miss the next one — exact entry, exact stop, no fluff.

0 · Reply

Dragan7 Jul. 30 at 2:54 PM

$CORT Earnings are very good, but more important is guidance and future drugs in pipe-line. PDUFA is in December 2026. They already have significant results treating ALS ( Lou Gehrig ). This not fully discovered gem.

0 · Reply

gucag006 Jul. 30 at 2:29 PM

$CORT Happy squeeze! This morning's SP swing-up raises the shorties liabilities collectively by $250M. Ouch, it hurts!

1 · Reply

Corcept Therapeutics price target raised to $161 from $150 at Canaccord

2026-07-30T11:02:09.000Z - 7 hours ago

Corcept Therapeutics price target raised to $165 from $88 at Piper Sandler

2026-07-30T10:16:44.000Z - 8 hours ago

Corcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright

Jul 29, 2026, 5:00 PM EDT - 21 hours ago

Corcept Therapeutics Earnings Call Transcript: Q2 2026

Jul 29, 2026, 5:00 PM EDT - 21 hours ago

Corcept Therapeutics Earnings release: Q2 2026

Jul 29, 2026, 5:00 PM EDT - 21 hours ago

Corcept Therapeutics Quarterly report: Q2 2026

2026-07-29T20:30:29.000Z - 22 hours ago

Corcept Therapeutics reports Q2 EPS 36c, consensus 5c

Jul 29, 2026, 4:05 PM EDT - 22 hours ago

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

2026-07-29T11:16:47.000Z - 1 day ago

Corcept Therapeutics price target raised to $150 from $135 at Canaccord

2026-07-27T11:45:25.000Z - 3 days ago

Corcept Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research

Jul 22, 2026, 4:05 PM EDT - 7 days ago

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

2026-06-17T20:30:11.000Z - 6 weeks ago

Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome

Jun 17, 2026, 4:28 PM EDT - 6 weeks ago

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

2026-06-07T22:05:06.000Z - 7 weeks ago

Corcept announces presentation of new data from Catalyst, Momentum trials

May 29, 2026, 4:33 PM EDT - 2 months ago

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

2026-05-28T12:08:48.000Z - 2 months ago

Corcept Therapeutics price target raised to $135 from $110 at Canaccord

2026-05-28T10:10:27.000Z - 2 months ago

Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright

2026-05-27T14:36:43.000Z - 2 months ago

Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant

May 27, 2026, 8:00 AM EDT - 2 months ago

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

2026-05-13T13:38:36.000Z - 2 months ago

Corcept Therapeutics upgraded to Buy from Neutral at UBS

2026-05-13T09:35:12.000Z - 2 months ago

Corcept Therapeutics upgraded to Buy from Neutral at UBS

2026-05-04T10:17:31.000Z - 3 months ago

Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright

2026-05-01T11:37:49.000Z - 3 months ago

Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler

2026-04-30T21:06:37.000Z - 3 months ago

Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study

Apr 30, 2026, 5:00 PM EDT - 3 months ago

Corcept Therapeutics Earnings Call Transcript: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 3 months ago

Corcept Therapeutics Earnings release: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 3 months ago

Corcept Therapeutics Quarterly report: Q1 2026

2026-04-30T20:28:44.000Z - 3 months ago

Corcept Therapeutics reports Q1 EPS (30c), consensus (14c)

2026-04-30T20:28:17.000Z - 3 months ago

Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M

Apr 30, 2026, 4:05 PM EDT - 3 months ago

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

Apr 30, 2026, 4:05 PM EDT - 3 months ago

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Apr 23, 2026, 4:05 PM EDT - 3 months ago

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Apr 21, 2026, 1:09 PM EDT - 3 months ago

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Corcept Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 4:45 PM EDT - 3 months ago

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Mar 28, 2026, 2:45 PM EDT - 4 months ago

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

Mar 25, 2026, 1:18 PM EDT - 4 months ago

Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer

Mar 25, 2026, 12:43 PM EDT - 4 months ago

FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

Mar 18, 2026, 5:35 PM EDT - 4 months ago

Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated

Mar 11, 2026, 4:48 PM EDT - 5 months ago

Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 6:00 PM EDT - 5 months ago

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026

Feb 24, 2026, 5:00 PM EST - 5 months ago

Corcept Therapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

Corcept Therapeutics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

Corcept Therapeutics Earnings release: Q4 2025

Feb 24, 2026, 4:05 PM EST - 5 months ago

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Feb 19, 2026, 4:00 PM EST - 5 months ago

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

Feb 17, 2026, 4:05 PM EST - 5 months ago

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

Feb 9, 2026, 4:54 AM EST - 6 months ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

Jan 30, 2026, 2:20 PM EST - 6 months ago

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application

Jan 30, 2026, 10:36 AM EST - 6 months ago

Corcept shares tumble after FDA letter reveals warnings before drug rejection

Jan 22, 2026, 8:13 AM EST - 6 months ago

Corcept's cancer drug meets main goal in late-stage trial

Jan 22, 2026, 8:00 AM EST - 6 months ago

Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Jan 15, 2026, 10:31 AM EST - 7 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CTRE DCOM DOCN ENVA

Jan 14, 2026, 9:52 PM EST - 7 months ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT

aristocks Jul. 30 at 6:50 PM

0 · Reply

flychicken1991 Jul. 30 at 6:01 PM

0 · Reply

StocktwitsNews Jul. 30 at 5:53 PM

0 · Reply

Larry_wildman Jul. 30 at 5:17 PM

$CORT $GIFT

0 · Reply

Dragan7 Jul. 30 at 3:08 PM

1 · Reply

Dragan7 Jul. 30 at 3:00 PM

$CORT Second point: they are profitable, and highly candidate for M&A. Pharma must be looking.

0 · Reply

fda_tracker Jul. 30 at 2:57 PM

$CORT New PDUFA Date 2026-12-17 CORCEPT THERAPEUTICS INC Link: https://www.sec.gov/Archives/edgar/data/1088856/000162828026050613/cort-20260630.htm Calendar: http://www.fdatracker.com/fda-calendar/

0 · Reply

RazorbackAJ Jul. 30 at 2:55 PM

$CORT Up 9% from this call and stop loss moved to $115 and in deep profits. Follow so you don't miss the next one — exact entry, exact stop, no fluff.

0 · Reply

Dragan7 Jul. 30 at 2:54 PM

0 · Reply

gucag006 Jul. 30 at 2:29 PM

$CORT Happy squeeze! This morning's SP swing-up raises the shorties liabilities collectively by $250M. Ouch, it hurts!

1 · Reply

JFais Jul. 30 at 2:24 PM

$CORT- $120 now! Had it in Playbook, but failed to pull the trigger after ?s on liver AEs

0 · Reply

whiskas007 Jul. 30 at 2:23 PM

$CORT wha are the shorts doing ? 1 billion to cover

0 · Reply

Following_the_trend Jul. 30 at 2:11 PM

$CORT Congrats longs. CORT sure has picked up a decent following here over the years.

0 · Reply

johnnylawrencecobra Jul. 30 at 2:07 PM

$CORT $GIFT Thank you QB I bought some GIFT here

0 · Reply

moorenard1 Jul. 30 at 1:58 PM

$CORT Top cancer drug launches of all time Keytruda: $50MM Lifyorli: $47.6mm Revlimid: $32.4mm Herceptin: $30.5mm

0 · Reply

GetVector Jul. 30 at 12:52 PM

Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $CAPR, $CMCO, $CORT, $TDOC.

0 · Reply

Mikeqb20 Jul. 30 at 12:28 PM

$CORT Great job MAESTRO! Next up is his $GIFT Watch and miss out or BUY GIFT and make $$$

0 · Reply

TheAlmani Jul. 30 at 12:15 PM

$CORT H.C. Wainwright raised its price target on Corcept Therapeutics (NASDAQ: CORT) to $165 from $95 while maintaining a Buy rating. This update follows Corcept's second-quarter 2026 financial results, which surpassed consensus expectations. https://ca.investing.com/news/stock-market-news/hc-wainwright-raises-corcept-therapeutics-price-target-to-165-on-strong-q2-results-93CH-4763696

0 · Reply

OpenOutcrier Jul. 30 at 12:04 PM

$CORT (+19.2% pre) Corcept earnings beat by $0.35, revenue topped estimates https://ooc.bz/l/109205

0 · Reply

Cutlass Jul. 30 at 11:55 AM

$CORT Nice pop this morning, if you have some left to sell! I am out of shares 🙄

1 · Reply

whiskas007 Jul. 30 at 11:45 AM

$CORT diamonds forever ❤️

0 · Reply

topstockalerts Jul. 30 at 11:32 AM

Pre Market Top Gainers PT2 $DCX $XRX $BOOM $CORT $PRCH

0 · Reply

Market Cap	10.11B
Revenue (ttm)	761.41M
Net Income (ttm)	99.65M
EPS (ttm)	N/A
PE Ratio	260.34
Forward PE	171.12
Profit Margin	13.09%
Debt to Equity Ratio	0.00

Volume	3,107,108
Avg Vol	1,078,264
Day's Range	N/A - N/A
Shares Out	107.35M
Stochastic %K	55%
Beta	0.47
Analysts	Sell
Price Target	$85.83